Compare GNRC & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GNRC | CORT |
|---|---|---|
| Founded | 1959 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.1B | 9.7B |
| IPO Year | 2009 | 2001 |
| Metric | GNRC | CORT |
|---|---|---|
| Price | $185.68 | $69.95 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 22 | 5 |
| Target Price | ★ $288.50 | $142.60 |
| AVG Volume (30 Days) | 1.2M | ★ 1.2M |
| Earning Date | 10-28-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 5.48 | 1.13 |
| Revenue | ★ $4,209,147,000.00 | $761,407,000.00 |
| Revenue This Year | $17.20 | $52.09 |
| Revenue Next Year | $39.29 | $44.73 |
| P/E Ratio | ★ $33.89 | $61.24 |
| Revenue Growth | N/A | ★ 12.79 |
| 52 Week Low | $134.80 | $28.66 |
| 52 Week High | $296.44 | $126.38 |
| Indicator | GNRC | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 43.96 | 24.76 |
| Support Level | $178.87 | $30.24 |
| Resistance Level | $231.52 | $122.93 |
| Average True Range (ATR) | 10.09 | 4.70 |
| MACD | -0.23 | -0.14 |
| Stochastic Oscillator | 33.47 | 10.50 |
Generac designs and manufactures power generation equipment serving residential, commercial, and industrial markets. It offers standby generators, portable generators, lighting, outdoor power equipment, and a suite of clean energy products. Sales generated in the United States account for the majority of total sales.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.